Jounce Therapeutics Presents First Preclinical Data on Anti-CCR8 Antibody JTX-1811 and Vopratelimab Translational Data at The American Association for Cancer Research Virtual Annual Meeting - Preclinical data supports the development of JTX-1811, targeting CCR8, as a novel immunotherapy for the selective depletion of immunosuppressive tumor-infiltrating T-regulatory cells - -...

Jounce Therapeutics Initiates Phase 2 EMERGE Study of Vopratelimab in Combination with Ipilimumab in Patients with Non-Small Cell Lung Cancer or Urothelial Cancer - Commenced patient enrollment in Phase 2 clinical trial of vopratelimab in combination with ipilimumab - - Preliminary efficacy and relationship to biomarker data expected in 2020 - CAMBRIDGE,...

Jounce Therapeutics Completed Enrollment in First Cohort of Phase 1 Clinical Trial with its PD-1 Inhibitor, JTX-4014 CAMBRIDGE, Mass., Jan. 03, 2019 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and...